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We have recently described the first true genome-wide screen for CD4+ T-cell reactivity
directed against Mycobacterium tuberculosis (MTB) in latent TB-infected individuals. The
approach relied on predictions of HLA-binding capacity for a panel of DR, DP, and DQ alle-
les representative of those most commonly expressed in the general population, coupled
with high throughput ELISPOT assays. The results identified hundreds of novel epitopes
and antigens, and documented the novel observation that T cells in latent MTB infection
are confined to the CXCR3+CCR6+ phenotype and largely directed against three antigenic
“islands” within the MTB genome. In parallel, we have made generally available to the
scientific community the technical approaches and reagents developed in the process,
such as motifs, algorithms, and binding assays for several common HLA class II alleles,
and a panel of single allele HLA class II transfected cell lines representative of the most
frequent specificities in the general population. Recent efforts have been focused on char-
acterization of epitopes and antigens recognized by patients with activeTB and individuals
vaccinated with BCG, with the aim of providing the first systematic evaluation of the over-
lap between latent, active, and BCG cohorts. The definition of a broad range of epitopes
restricted by common HLA molecules, will facilitate development of diagnostic reagents,
allow a rigorous evaluation ofT-cell responses associated withTB infection in humans, and
enable the evaluation of the immunogenicity of different vaccine candidates. Furthermore,
it might suggest new candidates for vaccine and diagnostic development.
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TB AS A WORLDWIDE MEDICAL PROBLEM
Tuberculosis is the second leading cause of death from infectious
diseases worldwide (1). The World Health Organization (WHO)
estimates that approximately one-third of the world’s popula-
tion (two billion total) is infected with Mycobacterium tuberculosis
(MTB). MTB is responsible for 1.4 million deaths annually and 9
million new infections are reported each year. The majority of
infected individuals control the pathogen by mounting a suc-
cessful, long-lived, and protective immune response, leading to
either resolution or a clinically latent infection. Approximately,
10% of latently infected individuals subsequently develop active
TB (2, 3). The risk of developing active tuberculosis is higher
in immunocompromised individuals (due to age, corticosteroids,
malnutrition,HIV infection,etc.). Treatment is lengthy and expen-
sive, requiring a combination of antibiotics. In many parts of the
world, access to these drugs is limited and compliance with the
drug regime is often poor, thus precipitating the development of
drug-resistant strains. Worldwide, 3.7% of new cases and 20% of
previously treated cases are infected with multidrug-resistant TB
(MDR-TB), extensively drug-resistant TB (XDR-TB) and recently
virtually untreatable totally drug-resistant (TDR) strains (1, 4).
The prevalence of these drug-resistant cases, which complicates
the schedule and increases cost of treatment, has heightened
interest in the development of effective vaccines, and prompted
inclusion of MTB in the list of A–C pathogens. The vaccination
of children with Mycobacterium bovis BCG results in a 60–80%
decrease in the incidence of active tuberculosis. However, in most
developed countries BCG vaccination is not recommended due to
the relatively low incidence of disease and variable effectiveness
in preventing pulmonary TB in adults, a large fraction of active
disease cases.
CD4 T-CELL RESPONSES IN TB INFECTION
Due to the intracellular lifestyle of MTB, immunity relies on a
successful T-cell response against a repertoire of antigenic targets.
Defining this is central to understanding the immune response
against TB and it has been vigorously pursued. Human T-cell
responses to MTB involve CD4, CD8, CD1, and γδ T cells, though
protective immunity to MTB is commonly ascribed to a Th1 pro-
file (3, 5–8). CD4+ T cells are central to the defense against MTB, as
exemplified by the fact that HIV-infected patients are more suscep-
tible to primary TB infection, reinfection, and reactivation (9–11).
Seminal studies in human T-cell responses to MTB showed that
memory Th1 cells secreted IFNγ (12). It was further shown that
IFNγ has an essential role in the protective immunity to mycobac-
teria, as individuals with genetic defects in the IFNγ receptor
have an increased susceptibility to infection with mycobacteria
(13). Furthermore, TNFα is important in host resistance to TB,
as evidenced by studies following anti-TNFα therapy for autoim-
mune disease, where patients with LTBI have been observed to
develop active TB (14, 15). Other Th subsets and cytokines have
been shown to be involved in the T-cell response to MTB. Sev-
eral studies indicate that lower IFNγ/IL-4 or IFNγ/IL-5 ratios are
found in active TB patients compared to healthy TB controls (16,
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17). Furthermore, healthcare workers that have worked in close
proximity to TB patients, and subsequently developed TB, showed
increased IL-5 levels compared to healthcare workers that did not
develop TB (18). Definition of the exact role of Th2 responses
still requires more investigation. Furthermore, several studies sug-
gest that the capacity to secrete multiple cytokines can determine
pathogen clearance versus persistence (19). Indeed, several stud-
ies in TB have suggested that multifunctional T cells are not only
a potential correlate of protection, but have also been implicated
in pathology (20–23). Recently, MTB-specific T-cell expression of
IL-17 has been described (24–27). It has been demonstrated that
the BCG vaccine and purified protein derivative (PPD) are able to
expand memory CD4+IL-17+ cells (24, 26). Furthermore, IL-17+
T cells have been described in active TB patients, particularly in
those infected by MDR MTB strains (27, 28), suggesting a path-
ogenic role for this cytokine. There is also evidence for IL-10 as
a factor in humans with active TB, where IL-10 mediates inhi-
bition of antigen presentation to T cells, and therefore mediates
a decreased ability to clear infection contributing to TB patho-
genesis (29). IL-10 has been shown to be elevated in serum from
active pulmonary TB patients (30). Therefore, the involvement of
different Th subsets in TB infection remains to be clarified and
definition of human CD4+ T-cell epitopes to specifically track
pathogen-specific T-cell subsets remains a high priority.
THE CONCEPT OF HLA PROMISCUITY
T cells recognize specific complexes formed between MHC mole-
cules and particular peptide epitopes. Accordingly, a given epitope
will elicit a T-cell response only in individuals expressing MHC
molecules having the capacity to bind it with sufficiently high
affinity. Both class I and class II MHC molecules are extremely
polymorphic, and thousands of different variants are known in
humans (31, 32). The most frequent HLA class II alleles with pop-
ulation coverage of almost 90% at each locus are shown in Table 1.
Much of the polymorphism is concentrated on residues located
in the peptide-binding groove, giving each allelic variant a dis-
tinct binding specificity. As a result, the prediction, identification,
and validation of epitopes restricted by each HLA type represent
tasks of such complexity as to be practically unfeasible. Further,
different MHC types are expressed at dramatically different fre-
quencies in and across different ethnicities. Thus, without careful
consideration, ethnically unbiased population coverage is difficult
to obtain.
One mean of circumventing the problem is to focus on the
HLA types that are most widely represented in different ethnici-
ties worldwide (Table 1), while at the same time selecting epitopes
that are capable of binding multiple common HLA types (promis-
cuous epitopes). In this respect, it has been found that both class
I and II HLA molecules can be classified into groups, denom-
inated as supertypes that reflect shared or largely overlapping
peptide-binding repertoires and specificities. Indeed, a large body
of evidence demonstrates that the repertoire of peptides bound
by different HLA class II molecules significantly overlap (32), and
peptides with promiscuous binding capacity are also quite com-
mon [see, e.g., (34, 35)]. Overlaps in the repertoires of DRB1 and
DRB3/4/5 molecules, leading to the definition of a DR supertype,
as well as the identity of well-characterized CD4 T-cell epitopes
Table 1 | Genotype and phenotype frequencies of HLA class II alleles.
Locus Allele Genotype
frequency
Phenotype
frequency
DRB1 DRB1*01:01 2.8 5.4
DRB1*03:01 7.1 13.7
DRB1*03:02 1.1 2.1
DRB1*04:01 2.3 4.6
DRB1*04:02 1.1 2.2
DRB1*04:03 2.3 4.5
DRB1*04:04 1.9 3.8
DRB1*04:05 3.1 6.2
DRB1*04:07 2.4 4.8
DRB1*04:11 1.6 3.3
DRB1*07:01 7 13.5
DRB1*08:02 2.5 4.9
DRB1*09:01 3.1 6.2
DRB1*11:01 6.1 11.8
DRB1*11:02 1.1 2.2
DRB1*11:03 0.3 0.5
DRB1*11:04 1.4 2.8
DRB1*12:01 2 3.9
DRB1*13:01 3.2 6.3
DRB1*13:02 3.9 7.7
DRB1*13:03 1.2 2.4
DRB1*13:04 0.1 0.2
DRB1*14:01 3.4 6.7
DRB1*14:02 2.8 5.6
DRB1*15:01 6.3 12.2
DRB1*16:01 1 1.9
DRB1 Total 71.1 91.7
DRB3/4/5 DRB3*01:01 14 26.1
DRB3*02:02 18.9 34.3
DRB3*03:01 6.7 13
DRB4*01:01 23.7 41.8
DRB5*01:01 8.3 16
DRB5*01:02 5.1 9.8
DRB3/4/5 Total 76.7 94.6
DQA1/DQB1 DQA1*05:01/DQB1*02:01 5.8 11.3
DQA1*02:01/DQB1*02:01 5.7 11.1
DQA1*05:01/DQB1*03:01 19.5 35.1
DQA1*03:01/DQB1*03:02 10 19
DQA1*04:01/DQB1*04:02 6.6 12.8
DQA1*01:01/DQB1*05:01 7.6 14.6
DQA1*01:02/DQB1*05:02 3.5 6.9
DQA1*01:02/DQB1*06:02 7.6 14.6
DQA1/DQB1 Total 66.3 88.7
DPA1/DPB1 DPA1*02:01/DPB1*01:01 8.4 16
DPA1*01:03/DPB1*02:01 9.2 17.5
DPA1*01:03/DPB1*04:01 20.1 36.2
DPA1*01:03/DPB1*04:02 23.6 41.6
DPA1*02:02/DPB1*05:01 11.5 21.7
DPA1*02:01/DPB1*14:01 3.8 7.4
DPA1/DPB1 Total 76.5 94.5
Average genotype and phenotype frequencies for individual alleles are based on
data available at dbMHC, as previously described by McKinney et al. (33). Alle-
les previously characterized in detail for binding specificity are highlighted in bold
(32).
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with promiscuous DR-binding capacity, have been known for over
a decade (34–36). Other studies have similarly addressed reper-
toire overlaps and the existence of corresponding supertypes for
DP (32, 37–39) and DQ (32, 40, 41).
Following upon earlier computational, structural, and func-
tional approaches to define class II supertypes (42–45), we utilized
a large library of HLA DR-, DQ-, and DP-binding data to define
seven different class II supertypes (main DR, DR4, DRB3, main
DQ, DQ7, main DP, and DP2) (32). The molecules associated
with the respective supertypes fell largely along lines defined by
MHC locus and reflect, in broad terms, commonalities in reported
peptide-binding motifs. Repertoire overlaps between molecules
within the same class II supertype were found to be similar in
magnitude to what has been observed for HLA class I supertypes.
Surprisingly, however, the degree to which repertoires between
molecules in the different class II supertypes overlapped was found
to be fivefold to tenfold higher than repertoire overlaps typically
noted between molecules in different class I supertypes. These
results highlight the existence of a high degree of repertoire over-
lap amongst all HLA class II molecules, regardless of supertype
association. Further, in terms of implications for epitope identifi-
cation studies, these data also validate the idea that broadly reactive
HLA class II epitopes can be defined.
HLA PROMISCUITY IMPLICATIONS FOR EPITOPE IDENTIFICATION
Peptides with highly promiscuous binding capacity are frequently
recognized by immune individuals (34, 46–49) and epitope
immunodominance is highly influenced by promiscuous recog-
nition in the context of multiple HLA class II molecules (50). Fur-
thermore, a dominant fraction of the pathogen or allergen-specific
response can be identified by selection of the most promiscuous
binding peptides using bioinformatic predictions (51–54). The
advantage of this approach is that it would identify the optimal set
of peptide candidates for immunogenicity testing, eliminating the
necessity of synthesizing a large number of overlapping peptides
and, more importantly, circumvent the need to test each one of
them for binding to numerous HLA class II molecules in vitro.
We have recently described the selection of a panel of HLA DR,
DQ, and DP specificities that provide worldwide population (phe-
notypic) coverage of almost 90% at each locus, and accounts for
over 66% of all genes at each locus (32) (Table 1). Considering
up to eight different class II alleles expressed per individual (i.e.,
up to two at each of the four class II loci – DRB1, DRB3/4/5, DQ,
and DP), this panel afforded coverage of at least four alleles in
over 95% of the individuals in four different study populations of
diverse ethnicity from the USA and South Africa (33). For each
of these allelic variants, single HLA class II allele-transfected cell
lines have been generated (33). These transfected cell lines can
be used for high throughput determination of HLA restriction,
enabling better characterization of T-cell responses, and facili-
tating the development of tetrameric staining reagents. Also, for
the vast majority of these alleles high throughput binding assays
have been established, peptide-binding motifs defined, and predic-
tive algorithms developed and made publically available (32, 55),
enabling efficient and thorough identification of candidate epi-
topes, as well as characterization of their HLA-binding capacity
and potential population coverage.
Taken together, these data highlight that broadly reactive HLA
class II epitopes can be identified, and that these promiscuous
epitopes can account for a large fraction of the specific immune
response. Further, the bioinformatic tools necessary to identify
candidate epitopes, as well as specific cellular and immunochem-
ical reagents to allow detailed characterization of epitope-specific
responses are available and have been well-validated in several
studies.
SCREEN OF A GENOME-WIDE LIBRARY OF MTB-DERIVED
PREDICTED HLA CLASS II EPITOPES IN LTBI DONORS
The MTB genome encodes more than 4,000 different open read-
ing frames (ORFs) (56), generally highly conserved amongst
different strains, including drug-resistant ones. Identification of
T-cell epitopes from such a large and complex target is a com-
plex task, yet necessary for disease monitoring, vaccine evalua-
tions, and development. A comprehensive genome-wide screen
for HLA class II epitopes was recently performed (57). This
genome-wide screen analyzed the reactivity of latent TB-infected
(LTBI) individuals from the San Diego area. LTBIs were ini-
tially chosen as representative of a patient population that is,
at least in part, capable of containing TB infection. Several 100
novel CD4-restricted epitopes and many antigens were identified
(57). Furthermore, this study documented the novel observa-
tion that T cells in latent MTB infection are confined to the
recently described CXCR3+CCR6+ phenotype (24, 58) and largely
directed against three antigenic “islands” within the MTB genome.
Still, important gaps in epitope knowledge remain, as also high-
lighted in the TB research community, in particular after the
disappointing results of the MVA85A BCG boost human vaccine
trial (59).
To enable a genome-wide screen for epitopes recognized by
LTBIs (57), protein sequences from five complete (CDC1551, F11,
H37Ra, H37Rv, and KZN 1435) MTB genomes and 16 draft assem-
blies available in the NCBI Protein database were aligned. To select
candidate promiscuous epitopes, the binding capacity of all pos-
sible 15-mer peptides was predicted for 22 HLA DR, DP, and
DQ class II alleles commonly expressed in the general popula-
tion and for which validated algorithms were available (32, 52).
This approach eliminates the need to test each peptide in vitro
for HLA class II binding, as well as the necessity of synthesizing
overlapping peptides. The resulting synthetic peptide library of
20,610 peptides (2–10 per ORF, average 5), were tested in high
throughput ex vivo IFNγ ELISPOT using circulating T cells from
LTBI donors. Each individual donor tested recognized 24 epitopes
on average, revealing striking heterogeneity of responses to MTB.
The epitopes identified were ranked on the basis of magnitude
of response to assess their relative dominance. Overall, the top
80 epitopes accounted for 75% of the total response and the top
175 epitopes accounted for 90% of the total response. The epi-
topes were mapped to individual MTB antigens using the H37Rv
as a reference genome. A total of 82 antigens were recognized by
more than 10% of LTBI donors, accounting for approximately
80% of the total response. Thus, natural immunity to MTB is
multiantigenic. Taken together, these results demonstrate the feasi-
bility, novelty, and success of the genome-wide screen for epitopes
recognized by LTBIs.
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CHARACTERISTICS OF HLA CLASS II RESTRICTED ANTIGENS
IDENTIFIED BY THE GENOME-WIDE APPROACH
The protein category and the genomic location of the identified
antigens were determined using the TubercuList database (60).
This revealed enrichment for responses against cell wall-associated
and secreted proteins, however, strong immune responses were
induced by both secreted and non-secreted proteins, consistent
with earlier antigen discovery efforts (61–63). The localization of
antigens recognized by the LTBI donors was visualized by plot-
ting the recognition data on a linear map of the MTB genome.
This revealed striking clusters of reactivity within certain regions
of the genome. In particular, three significant antigenic islands,
which encode 0.55% of the total ORFs, accounted for 42% of
the total response. All three islands were shown to contain ESX
protein pairs, such as the well-known Rv3875 (Early Secretory
Target-6,ESAT-6) and Rv3874 (Culture Filtrate Protein 10,CFP10)
(64), and two also contain Type VII secretion systems ESX-1
and ESX-3.
METHODS TO CHARACTERIZE AND VALIDATE IDENTIFIED EPITOPES
Characterization and tracking of pathogen-specific T cells can be
achieved once specific T-cell epitopes have been defined. Here, we
briefly review our published data relating to the characterization
of T cells derived from LTBI donors (57). A variety of approaches
were employed in parallel including multiparameter intracellu-
lar cytokine staining (ICS) assays, tetramer staining, and T-cell
libraries (65). It was found that CD4+ T cells recognizing epitopes
derived from different TB antigens were associated with similar
multifunctional cytokine expression patterns. The most frequent
CD4+ T cells were IFNγ+TNFα+IL-2+ or IFNγ+TNFα+, fol-
lowed by TNFα+ single producing CD4+ T cells. To a lesser
extent, TNFα+IL-2+, single IFNγ+, and single IL-2+ cells were
also detected.
To characterize the responding T cells in depth, HLA-epitope
tetramer reagents were prepared for representative epitopes for
staining of CD4+ purified cells. To overcome low T-cell fre-
quency, a magnetic bead enrichment technique was preformed
(50, 66). This allowed phenotypic characterization of epitope-
specific memory subsets (57) as well as Th subset characterization
(manuscript in preparation).
An alternative and complementary approach to ICS and
tetrameric staining reagents is the screening of T-cell libraries (65).
This high throughput method allows determination of frequency
and distribution of pathogen/antigen/epitope-specific T cells (67).
THE REPERTOIRE OF T-CELL EPITOPES IN THE DIFFERENT
CLINICAL MANIFESTATIONS OF MTB IS NOT FULLY DEFINED
The work described above developed reagents and approaches to
broadly characterize human T-cell epitopes in the general human
population (32, 33, 39, 41, 68), and characterized in detail the
T-cell epitopes recognized in a panel of model TB antigens (50).
Most importantly, using LTBI donor PBMCs, we performed the
first truly genome-wide screen of ex vivo human CD4+ MTB T-
cell reactivity. Since latently infected individuals are able to control
infection, they provided a logical relevant“first step” population to
study protective responses. Mapping T-cell responses from these
individuals identified immunodominant CD4+ T-cell antigens
associated with potentially protective responses, and thus relevant
to vaccine design.
According to most classifications, three primary and different
outcomes can follow MTB exposure. The first, active TB infec-
tion is usually associated with evidence of bacterial replication.
The second, LTBI, is usually associated with no disease symptoms
and an effective immune response. And thirdly, reactivation of
tuberculosis is often triggered by immunosuppression (69). MTB
is believed to express different proteins in different stages of infec-
tion that may give rise to stage-specific immune responses and
recognition of different antigens. Evidence of infection and stage-
specific antigens in humans has indeed been reported (70, 71). In
granulomas, MTB is believed to be in a dormant state, triggered by
a range of stress factors including hypoxia, low pH, NO, nutrient
deprivation, and host immune pressure (72). Under these condi-
tions, genes encoded by the DosR regulon are upregulated (73, 74)
and several antigens encoded by this regulon have been described
as preferentially recognized by individuals with LTBI (71, 75–77).
In addition, some proteins have been described and referred to
as “resuscitation antigens” (78, 79). These are small bacterial pro-
teins that promote proliferation of dormant mycobacteria, and are
therefore believed to be involved in the reactivation of MTB (80).
However, these antigens have not been described as being prefer-
entially associated with a certain stage of infection. The availability
of prediction methods and high throughput assays makes it possi-
ble to investigate genome-wide disease stage-specific TB reactivity
and they can be applied to other pathogen systems.
VACCINATION AGAINST TB: NEED FOR REAPPRAISAL OF
BCG
One of the long-term strategies essential for control of the global
TB epidemic is effective vaccination. The only available licensed
TB vaccine to date, BCG, protects against disseminated tubercu-
losis in young children but offers very variable protection against
pulmonary tuberculosis (the contagious transmittable form of the
disease) in children and adults (81–83).
Several candidate TB vaccines are in clinical trial and many
of them are designed to boost the BCG response. One candidate
is MVA85A (modified Vaccinia Ankara virus expressing antigen
85A; Rv3804c), which was developed as a heterologous boost for
BCG (84, 85). Rv3804c is highly conserved amongst mycobacterial
species and it is present in all strains of BCG (86). MVA85A was
shown to boost pre-existing antimycobacterial immune responses
induced by either environmental mycobacteria or BCG vaccina-
tion (84). A recent phase 2b study demonstrated the feasibility of
a large efficacy trial of a new TB vaccine in a high-burden set-
ting (59). This landmark trial was the first infant efficacy trial in
over 50 years and its protocols and design will provide a reference
for future trials and vaccination strategies. Unfortunately, how-
ever, the trial failed to show any efficacy against MTB infection
in infants. Various hypotheses have been proposed to explain the
lack of efficacy. Amongst them is the hypothesis that boosting
with an antigen conserved in all mycobacterial species does not
provide any additional benefit over the immunity already induced
by exposure to environmental mycobacteria or BCG.
BCG was developed 90 years ago, but there is still a funda-
mental need for more knowledge regarding the actual mechanism
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of BCG immunogenicity, immunodominance, and crossreactivity
with TB. Several studies have investigated mycobacterial antigen-
specific human T-cell responses primed by vaccination with BCG
(62, 87, 88). However, a genome-wide screen for epitopes has
not previously been performed and would provide important
immunological answers. First, it is imperative to clearly define
the TB antigens that are primed following BCG vaccination. Iden-
tification of the antigens that are dominantly recognized following
BCG vaccination and also recognized in natural TB infection
would be important information for the design of BCG prime-
boosting vaccines. Conversely, identification of antigens that are
primed by BCG but are either weakly or not recognized in natural
TB infection could provide new vaccination strategies, as elimi-
nation of such antigens may improve BCG efficacy. Second, the
characterization of the T-cell phenotypes associated with recog-
nition of various antigens in the context of BCG vaccination
and natural infection may provide clues to the type of immune
response that might be most desirable, and additionally indicate
how the vaccine response should be modulated (i.e., by use of
specific adjuvants). Finally, the identification and characterization
of epitopes and antigens recognized following BCG vaccination
would provide important tools to monitor and evaluate different
vaccine candidates, or different vaccination strategies examining
dose, route, and the use of different adjuvants. In conclusion, as
it is likely that a large proportion of future vaccine recipients
will be BCG immunized at birth, and because several new vac-
cine candidates aim at either replacing or augmenting the efficacy
of the BCG vaccine (89–91), a thorough understanding of the
immune response following BCG vaccination and in different dis-
ease stages of TB infection will provide much needed information
toward future TB vaccine design and more efficacious predictive
diagnostic tests.
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